PFS and OS by CHR and molecular response at 3 months (all treatment arms combined). Analysis excludes patients with CHR or BCR-ABL ≤10% at baseline; only those patients who had not progressed (n = 258) or had not died (n = 262) by 3 months were included in (A) and (B), respectively. Four patients who had progressed but had not died by 3 months were included in (B). P < .0001 (log-rank) for CHR plus ≤10% vs CHR plus >10% at 3 months for PFS and OS. For CHR plus >10% vs no CHR at 3 months, P < .0001 (log-rank) for PFS and P = .0001 (log-rank) for OS.